Cetuximab + FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)
Phase 3Completed 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Epidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer
Conditions
Epidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer
Trial Timeline
May 1, 2004 โ Mar 1, 2011
NCT ID
NCT00154102About Cetuximab + FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)
Cetuximab + FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan) is a phase 3 stage product being developed by Merck for Epidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00154102. Target conditions include Epidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00154102 | Phase 3 | Completed |
Competing Products
13 competing products in Epidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| HER3-DXd | Daiichi Sankyo | Pre-clinical | 23 |
| Erlotinib | Astellas Pharma | Phase 2 | 52 |
| radio-labeled naquotinib + naquotinib | Astellas Pharma | Phase 1 | 33 |
| KRN23 | Kyowa Kirin | Phase 2 | 52 |
| SHR6390 + placebo | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| ABT-414 | AbbVie | Pre-clinical | 23 |
| Venetoclax + Fulvestrant | Roche | Phase 2 | 52 |
| Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine + Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine | Roche | Phase 3 | 77 |
| Palbociclib + Everolimus + Exemestane | Pfizer | Phase 1/2 | 40 |
| Palifermin | Swedish Orphan Biovitrum | Phase 1/2 | 40 |
| Crysvita (burosumab-twza) Treatment | Ultragenyx Pharmaceutical | Approved | 80 |
| FDX104 (4% Doxycycline) | Vyne Therapeutics | Phase 2 | 44 |
| ATR-04 | Azitra | Phase 1/2 | 33 |